Crispr Therapeutics shares tumble after significant earnings miss
Investing.com - Redburn-Atlantic has upgraded Brown Forman (NYSE:BFb) (NYSE:BF-B) from Sell to Neutral while lowering its price target to $30.00 from $40.00.
The firm cited Brown Forman’s stalled domestic market, which has led to a two-year downgrade cycle and derating of the stock.
Redburn-Atlantic noted that while the company still has "a compelling international growth opportunity," this comes with lower margins and increased tariff risk.
The analyst highlighted that cash conversion is expected to improve as an investment cycle concludes, which should offset negative earnings momentum.
The firm also pointed out that Brown Forman shares have derated to near multi-decade lows on price-to-earnings and enterprise value to invested capital ratios, providing valuation support for the stock.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.